

# ForPatients

by Roche

Macular Degeneration Age-Related Macular Degeneration Geographic Atrophy

## The long-term study of a new medicine (galegenimab) in people with a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

A Study Assessing the Long-Term Safety and Tolerability of RG6147 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

**Trial Status**  
Terminated

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT04607148 GR42558

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This clinical trial investigated a new medicine called “galegenimab.” People with a type of eye disease, “geographic atrophy secondary to age-related macular degeneration,” joined this study to find out if galegenimab treatments were safe and tolerable when given over a long time. Injections were given in the study eye, once every 4 or 8 weeks. The study treatment was planned for about 3 years. People underwent detailed eye examinations throughout the study. They were monitored for side effects, taking into consideration their nature, frequency, and severity.

**Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland)**  
Sponsor

**Phase 2**  
Phase

---

**NCT04607148 GR42558**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥60 Years

**Healthy Volunteers**  
No

---